recurrent disease, or data collected outside of the study period [2] . Less common lung neoplasms, such as carcinoid tumors and sarcomas, were also excluded. Of the remaining 81,105 eligible cases, 67,725 (83.5%) were NSCLC and 13,290 (16.4%) were SCLC [3] .
I
n the United States, lung cancer remains the most common cause of cancer-related death in both men and women. In 2008, it was estimated that lung cancer was the cause of 57% of cancer-related deaths, accounting for more deaths than breast, prostate, colon, rectal, and pancreatic cancers combined [1] . In 2009, the seventh edition of the TNM staging system for lung cancer was published by the International Union Against Cancer and the American Joint Committee on Cancer, based on proposals from the International Staging Project of the International Association for the Study of Lung Cancer (IASLC). In addition to non-small cell lung cancer (NSCLC), the new classification system will be used to stage both small cell lung cancer (SCLC) and bronchopulmonary carcinoid tumors. Many important revisions have been made to the TNM classification of lung cancer, and it is important for the radiologist to learn of these changes to provide more accurate clinical staging.
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of NSCLC in the IASLC study, clinical staging was available in 53,640 cases, whereas pathologic staging was available in 33, 933 cases [4, 6] . Overlap of data occurred when patients had both clinical and pathologic staging data available.
Using this large data set, survival statistics were calculated on the basis of the prognostic impact of various factors, including the T, N, and M designations as well as the final stage. Adjustments were made for cell type, sex, age, and the region where the data were collected.
All data were internally validated by origin and type of database. Additionally, external validation was obtained by testing the results against data collected from 1990 to 2002 in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database. 
T Designation
The tumor (T) designation is determined by the size of the primary tumor as measured in the long-axis diameter, extent of invasion of the primary tumor, and presence or absence of satellite nodules (Table 1) . Of 67,725 cases of NSCLC initially included in the IASLC database, 18,198 cases met the inclusion criteria for T designation analysis by having accurate clinical or pathologic staging and no metastatic disease. Using these cases, survival statistics were calculated based on the tumor size in patients who had undergone pathologic staging and surgical resection of the primary tumor. After surgical resection, patients were classified as R0 if there was no residual disease, R1 if microscopic residual disease was present, or R2 if gross residual disease was present. In patients with nodules measuring 2 cm or less that were completely surrounded by lung or visceral pleura, in the absence of nodal or extranodal metastatic disease (N0M0) and with complete resection of tumor (R0), the 5-year survival was 77%. By comparison, patients with nodules measuring greater than 2 cm but less than or equal to 3 cm using the same criteria had a 5-year survival of 71% [7] . On the basis of these statistically significant findings, the T1 designation has been divided into T1a and T1b ( Fig. 1 ) using the cut points of 2 and 3 cm, respectively.
Similar calculations were performed for completely resected lung masses greater than 3 cm in patients with pathologically staged N0M0 disease, and survival differences were optimized using cut points of 3, 5, and 7 cm. Tumors greater than 3 cm but less than or equal to 5 cm had a 5-year survival of 58%. Tumors greater than 5 cm but less than or equal to 7 cm had a 5-year survival of 49% [7] . On the basis of these findings, the T2 
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New TNM Classification for Lung Cancer designation has been divided based on size: tumors greater than 3 cm but less than or equal to 5 cm are designated as T2a and tumors greater than 5 cm but less than or equal to 7 cm are designated as T2b (Fig. 2) . For tumors greater than 7 cm, 5-year survival was 35%, which was similar to the 41% 5-year survival in pathologically staged T3N0M0 tumors [7] . This led to the reclassification of tumors greater than 7 cm as T3 (Fig. 3) .
In the previous edition of the TNM staging system, tumors were designated as T2 based not only on size but also on the extent of invasion. Tumors that invaded the visceral pleura and extended into the mainstem bronchus but were greater than 2 cm from the carina or caused atelectasis or postobstructive pneumonia without complete collapse of an entire lung were also classified as T2. However, alterations were necessary given the subdivision of the T2 designation on the basis of size in the revised staging system. Now any tumor less than or equal to 5 cm that meets any of the previously mentioned invasion criteria will be designated as T2a. Similarly, tumors greater than 5 cm but less than or equal to 7 cm with the same degree of invasion will be designated as T2b.
Accurate pathologic distinction between degrees of visceral pleural invasion has been shown to be an important prognostic indicator of survival [8] . However, because the visceral pleura may have anywhere from four to six histologic layers, the exact definition of visceral pleural invasion has been debated. Therefore, the IASLC has defined visceral pleural invasion as invasion extending through the elastic layer of the visceral pleura to the surface of the visceral pleura and has recommended the use of elastin stains for determination of this feature [8] .
Important changes have also been made to the T3 designation in the revised TNM classification. As stated previously, tumors greater than 7 cm in size are now designated as T3. Additionally, patients with satellite nodules in the same lobe, previously designated as T4, have been reclassified as T3 (Fig. 3 ). In patients with any pattern of nodal disease (any N), M0, and with or without complete resection (any R), 5-year survival was 28%, which is similar to the 31% for other T3 lesions using the same staging criteria [7] .
Many of the T3 designations will remain unchanged in the new revisions, primarily because their incidence was not high enough for accurate statistical survival analysis. Tumors that invade the diaphragm, phrenic nerve, mediastinal pleura, or parietal pericardium ( Tumors with a malignant nodule in a different lobe but in the same lung were classified 
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as M1 disease in the prior edition. However, the 5-year survival was 22% in patients pathologically staged with this pattern of disease, any pattern of nodal disease (any N), and with or without complete resection (any R). This is identical to the 22% 5-year survival in patients with other T4 tumors staged using similar pathologic criteria, leading to its reclassification as T4 [7] (Fig. 5 and Table 1 ). Other masses that meet the T4 designation include tumors that invade the mediastinum, carina, trachea, esophagus, great vessels, and heart (Fig. 6) . Invasion of the recurrent laryngeal nerve or vertebral body also will lead to designation of a tumor as T4 (Fig. 7) .
Because the incidence of invasion of these vital structures was relatively low in the study population, survival statistics could not be calculated, and therefore their designation remains unchanged.
Numerous changes have been made to the T designation for NSCLC between the new and prior TNM classifications (Table  1) . These changes were validated internally by the CRAB database and externally by the SEER database. Additionally, many recent publications have also validated these recommendations, adding further support to the new revisions [9] [10] [11] [12] . A, Axial CT image in 47-year-old woman shows 6.7 × 4.2 cm mass in lingula with invasion into chest wall (white arrow) and parietal pericardium (black arrow). Mass also invades into location of phrenic nerve (star), which was confirmed at pathology. B, Coronal chest CT image in 44-year-old woman shows 6.8 × 5.6 cm large cell carcinoma in right lower lobe with invasion of diaphragm but no hepatic invasion on pathologic evaluation. C, Coronal contrast-enhanced CT image in 66-year-old man shows complete atelectasis of left lung by 6.4 × 3.5 cm left hilar mass (white arrow), which is difficult to differentiate from surrounding atelectatic lung. Mass extends into mainstem bronchus (black arrow) 1.9 cm from carina but does not involve carina. A, Axial CT image in 51-year-old man shows 8.8 × 6.5 cm adenocarcinoma invading into mediastinum with invasion of right pulmonary artery, bronchus intermedius, and carina. B, Axial CT image in 63-year-old woman shows 7.2 × 6.1 cm squamous cell carcinoma extending into mediastinum, with invasion of trachea (white arrow) and esophagus (black arrow). C, Axial multiplanar reformation image 8 mm thick in 84-year-old woman shows large squamous cell carcinoma engulfing heavily calcified branches of left coronary artery (circle). Mass also invades and obstructs left inferior and superior pulmonary veins (arrow). Any mass that invades mediastinum, esophagus, trachea, carina, or great vessels is still designated as T4.
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N Designation
The nodal (N) designation is determined by the presence or absence of metastatic involvement of lymph nodes throughout the thorax (Table 1) . To determine if changes needed to be made to the N designation for NSCLC, 68,463 patients with M0 disease were evaluated. However, slight differences between the American Thoracic Society (MountainDressler) and Japanese nodal maps made statistical analysis difficult. To reconcile these differences, a new nodal chart was created that placed lymph nodes into seven specific zones: supraclavicular, upper, aorticopulmonary, subcarinal, lower, hilar-interlobar, and peripheral [13] (Fig. 8) . Although the nomenclature has changed, the general concept remains the same. Patients without nodal metastatic disease are designated as N0. Patients with N1 disease are defined as having metastatic involvement of lymph nodes in the ipsilateral peripheral or hilar zones (Fig. 9) . The N2 designation signifies metastatic extension to lymph nodes in the ipsilateral mediastinal (upper, aorticopulmonary, lower) or subcarinal lymph node zones (Fig. 10) . The N3 nodal designation includes metastatic involvement of any nodes in the supraclavicular lymph node zone or nodes in contralateral mediastinal, hilar-interlobar, or peripheral zones (Fig. 11) . When survival statistics were evaluated based on these nodal zones, survival continually decreased in both clinically and pathologically staged patients as the nodal designation increased. For instance, in those clinically staged with any T designation (any T) and without extranodal metastatic disease (M0), the 5-year survival was 42%, 29%, 16%, and 7% for the N0, N1, N2, and N3 designations, respectively [3] .
Survival differences were also calculated on the basis of the number of lymph node zones involved in any single nodal designation. For instance, in pathologically staged patients with any T and M0, those with nodal metastases to a single N1 zone had a median survival of 52 months whereas those with metastatic spread to nodes in multiple N1 zones had a median survival of only 31 months [3] . Similar decreases in survival were also seen in patients with multiple N2 nodal zone involvement (median survival 19 months) compared with those with disease in a single N2 nodal zone (median survival 35 months) [3] . Interestingly, these results showed improved survival in patients with a single N2 zone involved compared with those with multiple N1 zones involved. These findings, recently validated by an external study [14] , raised the possibility of subdividing the N1 and N2 classifications into N1a (singlezone N1), N1b (multiple-zone N1), N2a (single-zone N2), and N2b (multiple-zone N2). However, when these new categories were analyzed in conjunction with each T stage category, an insufficient number of patients were present in each group for valid statistical analysis. Although no changes will be made to the N designation in the seventh edition of the TNM classification, the above findings suggest that overall disease burden, in addition to the anatomic location of pathologically involved lymph nodes, contributes to survival.
M Designation
The M designation refers to the presence or absence of metastatic disease within or outside of the thorax (Table 1) . For evaluation of the M designation, survival statistical analyses were performed on 5,592 clinically staged T4M0 and M1 patients. Clinically staged patients with pleural dissemination of disease, any degree of nodal metastases (any N), and no extranodal metastatic disease (M0) had 1-year and 5-year survival of 36% and 2%, respectively, similar to the 45% 1-year and 3% 5-year survival in those with contralateral lung nodules. This is significantly worse survival than the 53% 1-year and 15% 5-year survival in clinically staged patients with other T4, any N, and M0 lesions [15] . Based on these findings, dissemination of disease to the pleura or pericardium as well as metastatic nodules to the opposite lung will now be designated as M1a (Fig. 12) . Metastatic disease outside of the thorax, with a significantly worse 1-year and 5-year survival of 22% and 1%, respectively, has been reclassified as M1b [15] (Fig. 13) . Although there was a small but significant survival difference between those with single and multiple sites of extrathoracic metastatic disease, not enough cases were available for analysis to support further subdivision of the M1b classification [15] .
As with the T and N descriptors, external validation has confirmed the importance of the revisions to the M descriptor [11, 12] . When 12,901 patients with T4 or M1 disease were evaluated from the California Cancer Registry, the analyses confirmed that the revised M descriptors are better correlated with survival when compared with the prior edition of the TNM staging system [12] . The only discrepancy was the decreased survival in patients with dissemination of disease to the pericardium, a group with survival similar to those with distant metastatic disease.
Small-Cell Lung Cancer
Unlike NSCLC, SCLC is seen almost exclusively in smokers and is known for its rapid A, Coronal CT image in 48-year-old woman with increasing hoarseness and left arm weakness shows large mass invading mediastinum with encasement of aorta, left subclavian artery, and left recurrent laryngeal nerve (black arrow). Mass also extends superiorly into soft tissue of neck with edema of subcutaneous tissues on left due to paralysis from brachial plexus invasion (white arrow). B, Axial CT image in 55-year-old man with adenocarcinoma at right apex invading vertebral body and compressing spinal cord. Any tumor that invades recurrent laryngeal nerve or vertebral body is designated as T4, which is unchanged from prior system.
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doubling time, high growth fraction, early development of metastatic disease, and initial sensitivity to chemotherapy and radiation [16] [17] [18] . Once thought to represent nearly a quarter of all cases of newly diagnosed lung cancer, the incidence of SCLC has steadily declined [19] . Despite its initial response to treatment, the long-term survival of patients with SCLC continues to be much worse than that of patients with NSCLC [18] .
Of the 81,015 patients with primary lung cancers analyzed in the CRAB database, SCLC comprised 13,290 (16.4%) cases. Unlike NSCLC, the staging of SCLC had previously been subdivided into two main categories, limited disease and extensive disease. Limited disease was classified as disease limited to a single hemithorax, although local extension of the primary tumor and supraclavicular lymphadenopathy could be present if they could be included in the same radiation port as the primary B, Corresponding PET image shows 18 F-FDG uptake in both nodule and lymph node. Metastatic disease to lymph nodes in ipsilateral hilum is designated as N1, which is unchanged.
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tumor [20, 21] . All other disease was staged as extensive disease.
Of the 13,290 cases of SCLC, 3,430 cases of clinically staged SCLC without distant metastatic disease and with full TNM data were available for statistical analysis. Except for the lack of statistical significance between those with N0 and N1 disease, analysis showed a significant decrease in survival as both the T and N designations increased [21] . Similarly, except for a very small subgroup of eight stage IIA patients that was a statistical outlier, survival decreased as the stage increased [21] . Given these findings, the IASLC has recommended that the new TNM staging system be applied to SCLC (Fig. 14) . This recommendation is supported by external validation that has also shown survival being more accurately predicted using the revised TNM staging system [22] .
Bronchopulmonary Carcinoid Tumors
Bronchopulmonary carcinoid tumors are malignant neuroendocrine tumors that are divided into typical and atypical subtypes based on pathologic criteria. Carcinoid tumors exist within a spectrum of neuroendocrine tumors of the lung that range from low-grade typical carcinoid tumors to intermediate-grade atypical carcinoid tumors and high-grade small cell carcinomas and large cell carcinomas [23] . Using combined data from both the IASLC and SEER databases, survival analysis was performed on 1,829 pathologically staged patients with bronchopulmonary carcinoid tumors using the revised TNM staging criteria. As with NSCLC and SCLC, as the T, N, and M designations of bronchopulmonary carcinoid tumors independently increased, there was a statistically significant decrease in 5-year survival. Similarly, as the stage increased, 5-year survival decreased [8] . On the basis of these findings, it has been recommended that bronchopulmonary carcinoid tumors be staged using the newly revised TNM classification (Fig. 15) .
Prognostic Factors
Of the prognostic factors evaluated, pathologic stage, sex, cell type, and age were all independently significant [24] (Table 2 ). These factors were also significant when clinically staged cases were evaluated in a separate analysis [2] . Earlier stage of disease at the time of diagnosis, female sex, and younger age were all favorable prognostic factors [24] . In terms of cell type, patients with bronchioloalveolar carcinoma, either pure or mixed, have the best survival across all calculations [24] . This survival benefit is well described in the literature [25] [26] [27] [28] [29] [30] . Survival in patients with adenocarcinomas and squamous cell carcinomas was similar when calculated across age and sex. However, when survival was calculated after making adjustments for pathologic stage, cell type, sex, and age, there was a significant survival advantage in those diagnosed with squamous cell carcinomas compared with adenocarcinomas and large cell carcinomas [24] . A similar survival advantage was also noted in patients with squamous cell carcinomas who were clinically staged with IIIA disease [2] . Although this would suggest some survival advantage in those with squamous cell carcinoma compared with these two cell types, this benefit is debated in the literature [31] [32] [33] [34] [35] .
Smoking history was only available in 2,467 of the 9,173 pathologically staged patients. Current smokers had an increased incidence of squamous cell carcinoma as well as an overall worse prognosis when compared with never smokers and prior smokers [24] . These findings have been validated in multiple external studies [26, [36] [37] [38] . Prognosis between former smokers and never smokers was less well-defined and in most 
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instances, there was no survival difference between these two subsets [24] .
Performance status was available in 3,027 of the 9,173 pathologically staged patients with NSCLC. Decreased performance status was associated with an increased mortality and was shown to be an independently significant factor in determining survival [24] . A similar benefit was shown in clinically staged patients [2] .
Of the 13,290 cases of SCLC, prognostic factors were evaluated in 6,609 clinically staged patients. Using the prior system for the staging of SCLC, 2,870 patients had limited disease and 3,739 had extensive disease. As seen with NSCLC, increasing age, male sex, and decreased performance status are all associated with decreased survival [2] . Extensive disease was also associated with a worse survival than in those patients with limited disease [2] .
Additional factors such as biologic markers, genetic markers, and functional imaging with PET have shown significant prognostic implications in the literature [2, 39, 40] . However, because the data in the CRAB database were collected from 1990 to 2000, this information was not available for statistical analysis.
Changes to the Staging System
In addition to revising the T, N, and M designators, significant changes to the final staging system were made to best correlate decreasing survival with increasing stage (Table 3) . At the same time, changes were made to prevent overlap in the survival curves between the different stages. In the absence of metastatic disease, all T4 tumors with N0 or N1 nodes have been downstaged from IIIB to IIIA. T2b masses with N0M0 disease will be upstaged from IB to IIA and T2a masses with N1M0 disease will be downstaged from IIB to IIA [3] .
Treatment Implications
By making adjustments to the T designation, M designation, and final stage based on both short-and long-term survival characteristics, the revised staging system for lung cancer is more accurately correlated with survival when compared with the prior staging system. Importantly, survival statistics from external studies have also confirmed the validity of these changes. Not only are these changes better correlated with survival, but they also more closely reflect trends in both definitive and palliative treatment. For instance, in the prior TNM revision, patients with tumors designated as T4 on the basis of invasion were at least staged as IIIB, even those with N0M0 disease. Although these patients were classically considered nonsurgical, successful resection with improved survival has been shown to be possible in select patients with direct invasion of the mediastinum, carina, pulmonary artery, vertebral body, superior vena cava, aorta, and left atrium [41] [42] [43] [44] [45] [46] [47] . These findings support the shift of locally invasive T4 tumors from stage IIIB to IIIA in the absence of N2 or N3 and M1a or M1b disease. Conversely, although no distinction was made between T4 tumors due to invasion and T4 tumors due to malignant pleural or pericardial disease in the prior revision, those tumors with malignant pleural or pericardial dissemination were clinically subcategorized as "wet IIIB." Those patients were deemed inappropriate candidates for definitive local therapy and thus were clinically regarded as having stage IV disease and treated only with systemic therapy [42, 45, 48] . Patients with satellite nodules in the same lobe and in the same lung but a different lobe, even in the absence of nodal metastases, would have been staged as IIIB and IV, respectively. According to the prior system, this staging would have precluded these patients from A B Fig. 14-Classification of small cell lung cancer (SCLC) using revised TNM system. Axial CT image in 59-year-old woman shows 6.2-cm SCLC extending into mediastinum and invading pulmonary artery without evidence of disease elsewhere (T4N0M0). SCLC should be staged using new TNM classification for lung cancer. New TNM Classification for Lung Cancer attempted surgical resection. However, many patients with this pattern of disease did undergo surgical resection and their outcomes were much improved compared with patients with distant metastatic disease [45, [49] [50] [51] . This surgical evidence further supports the shift in staging in the revised seventh edition of the TNM classification of lung cancer. Although staging can help direct therapy, it is important to remember that prospective clinical trials should be used to define optimal patient treatment and not staging systems based on retrospective survival data. For SCLC, radiotherapy and chemotherapy remain the mainstays of treatment [18] . However, a more well-defined tumor and nodal classification system will allow more precise treatment. This precision will be of growing importance as increased radiotherapy doses or more aggressive combined therapies are explored for patients with more localized disease [21] . Tumor size and invasion also can help determine treatment in SCLC. The term "limited disease" makes no distinction between a small intraparenchymal SCLC without nodal disease and a large mass invading the mediastinum with metastatic disease to multiple ipsilateral lymph nodes. This is an important distinction because the treatments can differ. Studies have shown that even when using the prior TNM classification, patients with stage I and possibly those with stage II SCLC can benefit from surgery and neoadjuvant chemotherapy, whereas those with more extensive localized disease should receive radiation and chemotherapy alone [52] [53] [54] .
Limitations
Despite the extensive power of the study, there are some limitations to the revised staging system for lung cancer. The new system is based on retrospective data that were primarily collected from databases not specifically designed to study the TNM classification of lung cancer [55] . Although tumor size was often included in the data, more precise information such as the exact site of tumor invasion and extent of lymph node involvement was often omitted. For this reason, much of the T3 and T4 classification remains unchanged, and no changes were made to the N classification despite significant survival differences in those with single versus multiple nodal zone involvement. Additionally, important tumor characteristics, such as the presence or absence of lymphangitic spread of tumor, were not evaluated. Prognostic information based on tumor biology and tumor genetics was not included in the study because most of these data were not widely available. Factors such as the reliability and accuracy of imaging in clinical staging and the prognostic impact of PET imaging were not addressed. Staging and treatment strategies were not uniform because the data were collected from 46 databases across 19 countries. Finally, although the new system is the best method to date to predict patient survival, all of the survival data comes from retrospective analysis and has not been tested prospectively. Given these limitations, a prospective database is currently being developed to assess the validity of each component T1a  T1  IA  IIA  IIIA  IIIB   T1b  T1  IA  IIA  IIIA  IIIB   T2a  T2  IB  IIA (IIB)  IIIA  IIIB   T2b  T2  IIA  IIB  IIIA  IIIB   T3 (> 7 
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of the TNM classification as well as to assess multiple other factors that are important in lung cancer staging and prognosis [55] .
Conclusion
Many important changes have occurred with the adoption of the seventh edition of the TNM staging system for lung cancer. These changes are better correlated with survival characteristics and current trends in definitive and palliative therapy. Because imaging plays such a crucial role in the evaluation of lung cancer, it is imperative that radiologists become well versed in the new revision of the TNM staging system to optimize patient care.
